SCHEMBL2472121

SCHEMBL2472121

Cc1onc(-c2ccccc2)c1-c1cn(-c2ccc(F)cc2)cn1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 6/20 0.50
PTGS1 P23219 3/20 0.50
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45
NLRP3 Q96P20 1/20 0.45
HTT P42858 1/20 0.45
KMT2A Q03164 1/20 0.44
ATM Q13315 1/20 0.44
MAPT P10636 2/20 0.42
MAPK14 Q16539 2/20 0.42
TDP1 Q9NUW8 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
MAPK13 O15264 1/20 0.40
MAPK12 P53778 1/20 0.40
MAPK10 P53779 1/20 0.40
MAPK11 Q15759 1/20 0.40
MT-CO2 P00403 2/20 0.40
CA12 O43570 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2473712 0.94 PTGS2 (0.48) PTGS2PTGS1HTTMAPK14TDP1
SCHEMBL2470757 0.91 PTGS2 (0.56) PTGS2PTGS1NPC1RAB9ANLRP3
SCHEMBL2468959 0.91 PTGS2 (0.50) PTGS2PTGS1NPC1RAB9ANLRP3
SCHEMBL2477859 0.90 HTT (0.55) PTGS2PTGS1NPC1RAB9ANLRP3
SCHEMBL2474103 0.88 PTGS2 (0.48) PTGS2PTGS1NPC1RAB9ANLRP3
SCHEMBL2476849 0.88 PTGS2 (0.48) PTGS2PTGS1NPC1RAB9ANLRP3
SCHEMBL2473617 0.88 NPC1 (0.46) PTGS2PTGS1NPC1RAB9ANLRP3
SCHEMBL2471844 0.88 NPC1 (0.61) PTGS2PTGS1NPC1RAB9ANLRP3
SCHEMBL2468902 0.87 PTGS1 (0.47) PTGS2PTGS1NPC1RAB9ANLRP3
SCHEMBL2473840 0.87 MAPK14 (0.45) PTGS2PTGS1MAPK14TDP1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1968973-B1 ARYL-ISOXAZOL-4-YL-IMIDAZOLE DERIVATIVES HOFFMANN LA ROCHE (CH) 2011-10-05 EP claimed
CN-101351461-A Aryl-iso  oxazol-4-yl-imidazole derivatives HOFFMANN LA ROCHE (CH) 2009-01-21 CN claimed
EP-1968973-A2 ARYL-ISOXAZOL-4-YL-IMIDAZOLE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2008-09-17 EP claimed
US-7414061-B2 Aryl-isoxazol-4-yl-imidazole derivatives HOFFMANN-LA ROCHE INC. (US) 2008-08-19 US claimed
US-20070161654-A1 Aryl-isoxazol-4-yl-imidazole derivatives HOFFMANN-LA ROCHE INC. 2007-07-12 US claimed
WO-2007074078-A2 ARYL-ISOXAZOL-4-YL-IMIDAZOLE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2007-07-05 WO claimed
EP-1968973-B1 ARYL-ISOXAZOL-4-YL-IMIDAZOLE DERIVATIVES HOFFMANN LA ROCHE (CH) 2011-10-05 EP disclosed
CN-101351461-B Aryl-isoxazol-4-yl-imidazole derivatives HOFFMANN LA ROCHE 2011-09-07 CN disclosed
CN-101351461-A Aryl-iso  oxazol-4-yl-imidazole derivatives HOFFMANN LA ROCHE (CH) 2009-01-21 CN disclosed
EP-1968973-A2 ARYL-ISOXAZOL-4-YL-IMIDAZOLE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2008-09-17 EP disclosed
US-7414061-B2 Aryl-isoxazol-4-yl-imidazole derivatives HOFFMANN-LA ROCHE INC. (US) 2008-08-19 US disclosed
US-20070161654-A1 Aryl-isoxazol-4-yl-imidazole derivatives HOFFMANN-LA ROCHE INC. 2007-07-12 US disclosed
WO-2007074078-A2 ARYL-ISOXAZOL-4-YL-IMIDAZOLE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2007-07-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070161654-A1 Aryl-isoxazol-4-yl-imidazole derivatives GABRA5, GABRA4, GABRA1 PTGS2 3762/4885PTGS1 2693/4885NPC1 1036/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.